Can immunotherapy cause thrombocytopenia?

Can Immunotherapy Cause Thrombocytopenia?

Yes, immunotherapy can cause thrombocytopenia, though it is rare (<1% incidence), but potentially severe or even fatal when it occurs. This immune-related adverse event (irAE) is well-documented with immune checkpoint inhibitors (ICIs), particularly PD-1/PD-L1 and CTLA-4 inhibitors 1, 2.

Epidemiology and Clinical Characteristics

The incidence of immunotherapy-induced thrombocytopenia varies by agent and combination:

• Monotherapy: Approximately 1-4% of patients develop hematologic toxicities 2
• Combination therapy (anti-PD-L1 + anti-CTLA-4): Over 90% of affected patients experience grade 3 toxicity, compared to ~70% with monotherapy 2
• Mortality risk: Up to 20% in affected patients 3

Timing of onset is variable but typically occurs:

• Median onset: ~12 weeks with combination therapy vs ~25 weeks with monotherapy 2
• Can occur as early as 40 days or as late as after treatment cessation 1, 4
• Most cases develop after approximately 3 cycles of ICI therapy 5

Pathophysiology

The mechanism involves a dual pathogenic process 6:

1. Immune-mediated platelet destruction: Autoantibody formation against platelets
2. Impaired megakaryopoiesis: Direct suppression of platelet production in bone marrow

Important caveat: Up to 40% of cases may be direct antiglobulin test (Coombs test) negative, which can delay diagnosis 2.

Clinical Recognition

Presenting symptoms include:

• Easy or excessive bruising, petechiae (especially lower legs)
• Bleeding from gums, nose, or in urine/stool
• Fatigue, pallor
• In severe cases: life-threatening hemorrhage 1, 3

Critical diagnostic pitfall: Immunotherapy-induced thrombocytopenia can be mistaken for chemotherapy-induced marrow toxicity, leading to delayed recognition and treatment 3. This is particularly problematic when ICIs are combined with myelosuppressive chemotherapy.

Management Algorithm

Immediate Actions Upon Diagnosis:

1. Discontinue ICI therapy immediately while investigating 2

2. Obtain urgent hematology consultation 1, 2

3. Diagnostic workup:

   • Complete blood count with differential
   • Peripheral blood smear
   • Direct antiglobulin test (recognizing it may be negative)
   • Consider bone marrow examination with relatively low threshold to exclude:
     • Marrow infiltration
     • Secondary myelodysplastic syndrome
     • Aplastic anemia
     • Other causes of pancytopenia 2

Treatment Based on Severity:

Grade 3-4 Thrombocytopenia (severe, life-threatening):

1. First-line therapy 1, 2:

   • High-dose corticosteroids (typically methylprednisolone 1-2 mg/kg/day)
   • IVIG 2 g/kg administered in divided doses per package insert 1
   • Platelet transfusion for active bleeding (though often ineffective) 3
   • Note: Approximately 70% respond to corticosteroids 2

2. Second-line therapy (for steroid-refractory cases, 10-15% of patients) 2, 5:

   • Rituximab
   • Mycophenolate mofetil (MMF)
   • Cyclosporine
   • Thrombopoietin receptor agonists (romiplostim, eltrombopag) - particularly effective for sustained recovery 7

3. Steroid tapering: Once platelet count improves to grade 1:

   • Grade 2 episode: wean over 4 weeks
   • Grade 3-4 episode: wean over 4-12 weeks 2

Rechallenge Considerations

ICI rechallenge is generally contraindicated after immunotherapy-induced thrombocytopenia 3. However, the evidence shows:

• Recurrence rate with rechallenge: approximately 10-15% 5
• Some patients have been successfully rechallenged without recurrence 7
• Decision framework: Consider rechallenge only if:
  • Complete resolution of thrombocytopenia achieved
  • Significant oncologic benefit expected
  • Close hematologic monitoring feasible
  • Patient fully informed of recurrence risk
  • Alternative cancer therapies inadequate

Prognosis

With prompt recognition and treatment:

• Most patients achieve significant symptom improvement 8
• Median hospitalization: 18 days for severe cases 8
• Important: 20% may have persistently abnormal blood counts even after treatment 2
• Long-term follow-up shows patients can remain stable after discharge with appropriate management 8

Key Clinical Pearls

• High-risk population: Patients with metastatic bone cancer receiving ICIs plus denosumab may have higher incidence (7.45% in one series) 8
• Delayed onset possible: Cases reported occurring after treatment cessation and even post-surgery 4
• Platelet transfusion alone is usually ineffective - immunosuppression is required 3
• Early recognition and intensive immunomodulatory therapy with interdisciplinary collaboration (oncology, hematology, nursing) are essential for optimal outcomes 8